• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    s41598-018-26050-y.pdf
    Size:
    2.419Mb
    Format:
    PDF
    Description:
    Full text, Open Access article
    Download
    Authors
    Lin, H
    Nikolic, I
    Yang, J
    Castillo, L
    Deng, N
    Chan, C
    Yeung, N
    Dodson, E
    Elsworth, B
    Spielman, C
    Lee, Brian Y
    Boyer, Z
    Simpson, K
    Daly, R
    Horvath, L
    Swarbrick, A
    Show allShow less
    Affiliation
    Cancer Division, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, 2010, Australia
    Issue Date
    2018-05-18
    
    Metadata
    Show full item record
    Abstract
    Docetaxel and cabazitaxel are taxane chemotherapy treatments for metastatic castration-resistant prostate cancer (CRPC). However, therapeutic resistance remains a major issue. MicroRNAs are short non-coding RNAs that can silence multiple genes, regulating several signalling pathways simultaneously. Therefore, synthetic microRNAs may have therapeutic potential in CRPC by regulating genes involved in taxane response and minimise compensatory mechanisms that cause taxane resistance. To identify microRNAs that can improve the efficacy of taxanes in CRPC, we performed a genome-wide screen of 1280 microRNAs in the CRPC cell lines PC3 and DU145 in combination with docetaxel or cabazitaxel treatment. Mimics of miR-217 and miR-181b-5p enhanced apoptosis significantly in PC3 cells in the presence of these taxanes. These mimics downregulated at least a thousand different transcripts, which were enriched for genes with cell proliferation and focal adhesion functions. Individual knockdown of a selection of 46 genes representing these transcripts resulted in toxic or taxane sensitisation effects, indicating that these genes may be mediating the effects of the microRNA mimics. A range of these genes are expressed in CRPC metastases, suggesting that these microRNA mimics may be functional in CRPC. With further development, these microRNA mimics may have therapeutic potential to improve taxane response in CRPC patients.
    Citation
    MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. 2018, 8(1): 7820 Sci Rep
    Journal
    Scientific Reports
    URI
    http://hdl.handle.net/10541/621107
    DOI
    10.1038/s41598-018-26050-y
    PubMed ID
    29777112
    Type
    Article
    Language
    en
    ISSN
    2045-2322
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41598-018-26050-y
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    • Authors: Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC
    • Issue date: 2017 Jun
    • Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    • Authors: Martin SK, Kyprianou N
    • Issue date: 2015
    • ERG induces taxane resistance in castration-resistant prostate cancer.
    • Authors: Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS
    • Issue date: 2014 Nov 25
    • Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
    • Authors: Fu W, Hong Z, You X, Din J, Chen B, Zhao B, Yuan G, Li Q
    • Issue date: 2019 Oct
    • Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
    • Authors: Yang Z, Chen JS, Wen JK, Gao HT, Zheng B, Qu CB, Liu KL, Zhang ML, Gu JF, Li JD, Zhang YP, Li W, Wang XL, Zhang Y
    • Issue date: 2017 Dec 8
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.